QQQ   307.12 (-0.53%)
AAPL   157.65 (-0.40%)
MSFT   275.23 (-0.42%)
META   200.68 (-1.06%)
GOOGL   101.03 (-1.40%)
AMZN   97.24 (-0.82%)
TSLA   189.19 (-1.37%)
NVDA   264.10 (-0.46%)
NIO   9.20 (+3.02%)
BABA   98.40 (+14.26%)
AMD   94.56 (-2.12%)
T   18.72 (-0.79%)
F   11.60 (+0.69%)
MU   59.28 (-0.85%)
CGC   1.81 (-3.72%)
GE   93.14 (-0.18%)
DIS   94.82 (-0.84%)
AMC   5.15 (+13.19%)
PYPL   72.70 (-0.82%)
PFE   39.99 (-0.57%)
NFLX   323.52 (-1.26%)
QQQ   307.12 (-0.53%)
AAPL   157.65 (-0.40%)
MSFT   275.23 (-0.42%)
META   200.68 (-1.06%)
GOOGL   101.03 (-1.40%)
AMZN   97.24 (-0.82%)
TSLA   189.19 (-1.37%)
NVDA   264.10 (-0.46%)
NIO   9.20 (+3.02%)
BABA   98.40 (+14.26%)
AMD   94.56 (-2.12%)
T   18.72 (-0.79%)
F   11.60 (+0.69%)
MU   59.28 (-0.85%)
CGC   1.81 (-3.72%)
GE   93.14 (-0.18%)
DIS   94.82 (-0.84%)
AMC   5.15 (+13.19%)
PYPL   72.70 (-0.82%)
PFE   39.99 (-0.57%)
NFLX   323.52 (-1.26%)
QQQ   307.12 (-0.53%)
AAPL   157.65 (-0.40%)
MSFT   275.23 (-0.42%)
META   200.68 (-1.06%)
GOOGL   101.03 (-1.40%)
AMZN   97.24 (-0.82%)
TSLA   189.19 (-1.37%)
NVDA   264.10 (-0.46%)
NIO   9.20 (+3.02%)
BABA   98.40 (+14.26%)
AMD   94.56 (-2.12%)
T   18.72 (-0.79%)
F   11.60 (+0.69%)
MU   59.28 (-0.85%)
CGC   1.81 (-3.72%)
GE   93.14 (-0.18%)
DIS   94.82 (-0.84%)
AMC   5.15 (+13.19%)
PYPL   72.70 (-0.82%)
PFE   39.99 (-0.57%)
NFLX   323.52 (-1.26%)
QQQ   307.12 (-0.53%)
AAPL   157.65 (-0.40%)
MSFT   275.23 (-0.42%)
META   200.68 (-1.06%)
GOOGL   101.03 (-1.40%)
AMZN   97.24 (-0.82%)
TSLA   189.19 (-1.37%)
NVDA   264.10 (-0.46%)
NIO   9.20 (+3.02%)
BABA   98.40 (+14.26%)
AMD   94.56 (-2.12%)
T   18.72 (-0.79%)
F   11.60 (+0.69%)
MU   59.28 (-0.85%)
CGC   1.81 (-3.72%)
GE   93.14 (-0.18%)
DIS   94.82 (-0.84%)
AMC   5.15 (+13.19%)
PYPL   72.70 (-0.82%)
PFE   39.99 (-0.57%)
NFLX   323.52 (-1.26%)
NYSEAMERICAN:MTNB

Matinas BioPharma - MTNB Stock Forecast, Price & News

$0.43
+0.02 (+4.84%)
(As of 03/28/2023 12:00 AM ET)
Add
Compare
Today's Range
$0.42
$0.44
50-Day Range
N/A
52-Week Range
$0.39
$1.00
Volume
363,241 shs
Average Volume
271,848 shs
Market Capitalization
$94.07 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.00

Matinas BioPharma MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
592.8% Upside
$3.00 Price Target
Short Interest
Healthy
0.52% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.11) to ($0.12) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.09 out of 5 stars


MTNB stock logo

About Matinas BioPharma (NYSEAMERICAN:MTNB) Stock

Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company, which focuses on enabling the delivery of life-changing medicines using its LNC platform technology. The firm's proprietary, disruptive technology utilizes lipid nano-crystals which can encapsulate small molecule drugs, oligonucleotides, vaccines, peptides, proteins, and other medicines potentially making them safer, more tolerable, less toxic, and orally bioavailable. Its anti-fungal product candidate, MAT2203, delivers a broad-spectrum fungicidal agent, amphotericin B, and is being developed to prevent invasive fungal infections in patients with acute lymphoblastic leukemia. The company was founded by Jerome D. Jabbour in May 2013 and is headquartered in Bedminster, NJ.

Receive MTNB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Matinas BioPharma and its competitors with MarketBeat's FREE daily newsletter.

MTNB Stock News Headlines

A 100% Win Rate In 2022…
The next 10 minutes could change your life. We've recorded a special sit-down interview with a reclusive millionaire who details how he's closed out winning trade after winning trade throughout the volatility of 2022. In fact, he hasn't closed a single losing trade since 2016. Sounds impossible? It's not - and he'll prove it to you. pixel
Q4 2022 Matinas BioPharma Holdings Inc Earnings Call
The "King Of Quants" sees 10X potential...
Eric Fry believes he just discovered America's next "Wealth Supercluster" and it's forming in the place you'd least expect. Investors are already flocking there for a chance at 1,000%+ returns. Here's how you could join them before it's too late...
MTNB Matinas BioPharma Holdings, Inc.
H.C. Wainwright Keeps Their Buy Rating on Matinas BioPharma (MTNB)
12 Hot Penny Stocks On the Rise
Deadly Fungi Are Infecting More Americans
See More Headlines
Receive MTNB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Matinas BioPharma and its competitors with MarketBeat's FREE daily newsletter.

MTNB Company Calendar

Last Earnings
11/07/2021
Today
3/28/2023
Next Earnings (Estimated)
5/10/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NYSEAMERICAN:MTNB
CIK
N/A
Fax
N/A
Employees
31
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$3.00
High Stock Price Forecast
$3.00
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+592.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-21,000,000.00
Pretax Margin
-658.63%

Debt

Sales & Book Value

Annual Sales
$3.19 million
Book Value
$0.17 per share

Miscellaneous

Free Float
197,277,000
Market Cap
$94.07 million
Optionable
Not Optionable
Beta
2.09

Key Executives

  • Jerome D. Jabbour
    President, Chief Executive Officer & Director
  • Keith A. Kucinski
    Chief Financial Officer
  • Raphael J. Mannino
    Chief Scientific Officer & Senior Vice President
  • James J. Ferguson
    Chief Medical Officer
  • Hui Liu
    Chief Technology Officer













MTNB Stock - Frequently Asked Questions

Should I buy or sell Matinas BioPharma stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Matinas BioPharma in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MTNB shares.
View MTNB analyst ratings
or view top-rated stocks.

What is Matinas BioPharma's stock price forecast for 2023?

2 Wall Street analysts have issued 12 month price objectives for Matinas BioPharma's stock. Their MTNB share price forecasts range from $3.00 to $3.00. On average, they expect the company's share price to reach $3.00 in the next year. This suggests a possible upside of 592.8% from the stock's current price.
View analysts price targets for MTNB
or view top-rated stocks among Wall Street analysts.

How have MTNB shares performed in 2023?

Matinas BioPharma's stock was trading at $0.5563 on January 1st, 2023. Since then, MTNB shares have decreased by 22.2% and is now trading at $0.4330.
View the best growth stocks for 2023 here
.

Are investors shorting Matinas BioPharma?

Matinas BioPharma saw a decline in short interest in March. As of March 15th, there was short interest totaling 1,120,000 shares, a decline of 26.8% from the February 28th total of 1,530,000 shares. Based on an average daily trading volume, of 312,900 shares, the short-interest ratio is presently 3.6 days.
View Matinas BioPharma's Short Interest
.

When is Matinas BioPharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 10th 2023.
View our MTNB earnings forecast
.

How were Matinas BioPharma's earnings last quarter?

Matinas BioPharma Holdings, Inc. (NYSEAMERICAN:MTNB) released its quarterly earnings results on Sunday, November, 7th. The company reported ($0.03) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by $0.01.

What other stocks do shareholders of Matinas BioPharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Matinas BioPharma investors own include KushCo (KSHB), Gran Tierra Energy (GTE), ADMA Biologics (ADMA), Bionano Genomics (BNGO), Pennsylvania Real Estate Investment Trust (PEI), CNBX Pharmaceuticals (CNBX), Organigram (OGI), Novan (NOVN), Zosano Pharma (ZSAN) and Aeterna Zentaris (AEZS).

What is Matinas BioPharma's stock symbol?

Matinas BioPharma trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "MTNB."

Who are Matinas BioPharma's major shareholders?

Matinas BioPharma's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Sargent Investment Group LLC (2.02%), Geode Capital Management LLC (0.83%), Millennium Management LLC (0.11%), Jane Street Group LLC (0.09%), Private Advisor Group LLC (0.09%) and Virtu Financial LLC (0.07%). Insiders that own company stock include Adam K Stern and Patrick G Lepore.
View institutional ownership trends
.

How do I buy shares of Matinas BioPharma?

Shares of MTNB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Matinas BioPharma's stock price today?

One share of MTNB stock can currently be purchased for approximately $0.43.

How much money does Matinas BioPharma make?

Matinas BioPharma (NYSEAMERICAN:MTNB) has a market capitalization of $94.07 million and generates $3.19 million in revenue each year. The company earns $-21,000,000.00 in net income (profit) each year or ($0.11) on an earnings per share basis.

How can I contact Matinas BioPharma?

Matinas BioPharma's mailing address is SUITE 302, 1545 ROUTE 206 SOUTH, BEDMINSTER, NJ 7921, United States. The official website for the company is www.matinasbiopharma.com. The company can be reached via phone at (908) 484-8805 or via email at mtnb@jtcir.com.

This page (NYSEAMERICAN:MTNB) was last updated on 3/28/2023 by MarketBeat.com Staff